According to Zhitong Finance App, Shiyao Group (01093) announced its 2026 interim results, with total revenue of 18.594 billion yuan (RMB, same below), up 40.1% year on year; shareholders' reported profit of 6.094 billion yuan, up 139.2% year on year; basic profit per share of 53.45 points. It is proposed to pay an interim dividend of HK18.00 cents per share.
The announcement stated that “leading innovation and creating excellent Shiyao” is the core vision of Shiyao people. Under the strategic leadership of the Chairman, the Group has always adhered to the “innovation+internationalization” two-wheel drive development strategy. By continuously increasing investment in R&D and continuously strengthening talent and team building, the Group's core competitiveness has been significantly enhanced, injecting momentum into the Group's long-term sustainable development.
The Group has an international R&D team of more than 2,000 people, with R&D centers in major cities in China and the US, focusing on core treatment fields such as anti-tumor, cardiovascular system, nervous system, respiratory system, anti-infection and digestive metabolism. We have pioneered the establishment of an industry-leading AI drug discovery technology platform and a world-leading delivery technology system, forming significant industry differentiation advantages. The R&D pipeline covers cutting-edge tracks such as ADC, antibody drugs, CAR-T products, peptides, and nucleic acid drugs. Overall, the Group has built eight technological innovation R&D platforms, including nanoparticles, messenger nucleic acid (mRNA), small interfering nucleic acid (siRNA), antibody/fusion proteins, cell therapy, and antibody-conjugated drugs, providing solid technical support for the discovery and transformation of innovative drugs.
In the first half of 2026, the Group obtained a total of 30 IND approvals, 7 key products were approved for listing, and 18 additional key phase III clinical studies were carried out. Since the beginning of the year, a number of R&D results have been published in top medical journals: the results of the phase I clinical study of SYS6010 for non-small cell lung cancer were accepted by CancerCell (impact factor 56.1); the phase III study results of docetaxel (albumin binding) combined with kn026 new adjuvant treatment for breast cancer were officially accepted by JamaOncology (influencing factor 23.9); the results of the phase III clinical study on patients with advanced breast cancer with albumin-conjugated paclitaxel (SYHX2011) were accepted by CancerCell CancerCommunications received it (impact factor 24.9). The above results reflect the recognition of the Group's research strength by top international journals. At the same time, the Group showcased core research results many times on top international academic platforms such as the American Cancer Society (AACR), the American Society of Clinical Oncology (ASCO), and the American Society of Gynecologic Oncology (SGO). In the first half of 2026 alone, the Group published 14 research results, including 5 oral reports, which received good international response and widespread industry attention. Currently, the Group has more than 200 innovative drugs and innovative formulations, including 90 macromolecules, 60 small molecules, and more than 50 novel formulations. Among them, there is no shortage of products with broad market prospects and significantly superior to existing treatments in terms of efficacy and safety.
CSPC Group's exploration in the field of AI pharmaceuticals began with the CADD (computer-aided drug design) laboratory established in 2011. At present, the group has established an AI drug discovery team spanning Shijiazhuang, Beijing and Shanghai, and formed a technical system with an “AI engine two-wheel drive drug discovery platform” as the core. The platform has enabled one-stop development from target discovery, molecular generation, structure prediction to ADMET (drug absorption, distribution, metabolism, excretion, and toxicity) prediction.
The group has mature and strong commercialization capabilities, a professional marketing team of more than 10,000 people, covering a wide range of medical institutions and retail channels across the country. We are actively promoting the sinking of the market, deepening the grass-roots market in the county area, and providing high-quality pharmaceuticals to more people. The mature sales system and rich commercialization experience provide a solid guarantee for the launch and market performance of the Group's innovative drugs.
Facing the future, the Group will continue to drive development with technological innovation and implement results with solid commercialization capabilities to help the Chinese pharmaceutical industry achieve high-quality development and bring welfare to more patients.